Murine pharmacokinetics and metabolism of penclomedine [3,5-dichloro-2,4- dimethoxy-6-(trichloromethyl)pyridine, NSC 338720]

Joel M Reid, D. A. Mathiesen, L. M. Benson, M. J. Kuffel, M. M. Ames

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Penclomedine, a highly substituted pyridine derivative, has been selected by the National Cancer Institute for evaluation as a potential anticancer agent based on antitumor activity observed in murine tumor models following i.v., p.o., and i.p. administration. We have developed a reverse-phase high performance liquid chromatography assay for PEN, and subsequently investigated murine pharmacokinetics and metabolism. Following rapid i.v. injection of PEN (300 mg/m2) to mice, plasma elimination was best described by a 2-compartment open model with an elimination phase half-life, total body clearance, and steady-state distribution volume of 69 min, 114 ml/min/m2, and 4800 ml/m2, respectively. While PEN displayed good p.o. absorption, bioavailability of PEN after p.o. administration was approximately 2% of that observed following i.v. administration. Metabolism contributed substantially to drug clearance, and total metabolites were slowly eliminated from plasma. After i.v. and p.o. administration of radiolabeled PEN, <0.2% of the parent drug was excreted in the 48-h urine, and 25-30% of the total radioactivity was recovered in urine. NADPH-dependent oxidative and reductive metabolism was observed when penclomedine was incubated with mouse microsomal preparations. Microsomal reductive metabolism of PEN led to formation of a metabolite tentatively identified as a molecule formed by dimerization of the radical species produced by cleavage of chlorine from the trichloromethyl moiety of penclomedine.

Original languageEnglish (US)
Pages (from-to)2830-2834
Number of pages5
JournalCancer Research
Volume52
Issue number10
StatePublished - 1992

Fingerprint

penclomedine
Pharmacokinetics
Urine
National Cancer Institute (U.S.)
Chlorine
Dimerization
Reverse-Phase Chromatography
NADP
Pharmaceutical Preparations
Antineoplastic Agents
Radioactivity
Biological Availability
Half-Life
High Pressure Liquid Chromatography
Injections
pyridine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Murine pharmacokinetics and metabolism of penclomedine [3,5-dichloro-2,4- dimethoxy-6-(trichloromethyl)pyridine, NSC 338720]. / Reid, Joel M; Mathiesen, D. A.; Benson, L. M.; Kuffel, M. J.; Ames, M. M.

In: Cancer Research, Vol. 52, No. 10, 1992, p. 2830-2834.

Research output: Contribution to journalArticle

Reid, Joel M ; Mathiesen, D. A. ; Benson, L. M. ; Kuffel, M. J. ; Ames, M. M. / Murine pharmacokinetics and metabolism of penclomedine [3,5-dichloro-2,4- dimethoxy-6-(trichloromethyl)pyridine, NSC 338720]. In: Cancer Research. 1992 ; Vol. 52, No. 10. pp. 2830-2834.
@article{0030f58d0db048fd84c091529f2ca954,
title = "Murine pharmacokinetics and metabolism of penclomedine [3,5-dichloro-2,4- dimethoxy-6-(trichloromethyl)pyridine, NSC 338720]",
abstract = "Penclomedine, a highly substituted pyridine derivative, has been selected by the National Cancer Institute for evaluation as a potential anticancer agent based on antitumor activity observed in murine tumor models following i.v., p.o., and i.p. administration. We have developed a reverse-phase high performance liquid chromatography assay for PEN, and subsequently investigated murine pharmacokinetics and metabolism. Following rapid i.v. injection of PEN (300 mg/m2) to mice, plasma elimination was best described by a 2-compartment open model with an elimination phase half-life, total body clearance, and steady-state distribution volume of 69 min, 114 ml/min/m2, and 4800 ml/m2, respectively. While PEN displayed good p.o. absorption, bioavailability of PEN after p.o. administration was approximately 2{\%} of that observed following i.v. administration. Metabolism contributed substantially to drug clearance, and total metabolites were slowly eliminated from plasma. After i.v. and p.o. administration of radiolabeled PEN, <0.2{\%} of the parent drug was excreted in the 48-h urine, and 25-30{\%} of the total radioactivity was recovered in urine. NADPH-dependent oxidative and reductive metabolism was observed when penclomedine was incubated with mouse microsomal preparations. Microsomal reductive metabolism of PEN led to formation of a metabolite tentatively identified as a molecule formed by dimerization of the radical species produced by cleavage of chlorine from the trichloromethyl moiety of penclomedine.",
author = "Reid, {Joel M} and Mathiesen, {D. A.} and Benson, {L. M.} and Kuffel, {M. J.} and Ames, {M. M.}",
year = "1992",
language = "English (US)",
volume = "52",
pages = "2830--2834",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Murine pharmacokinetics and metabolism of penclomedine [3,5-dichloro-2,4- dimethoxy-6-(trichloromethyl)pyridine, NSC 338720]

AU - Reid, Joel M

AU - Mathiesen, D. A.

AU - Benson, L. M.

AU - Kuffel, M. J.

AU - Ames, M. M.

PY - 1992

Y1 - 1992

N2 - Penclomedine, a highly substituted pyridine derivative, has been selected by the National Cancer Institute for evaluation as a potential anticancer agent based on antitumor activity observed in murine tumor models following i.v., p.o., and i.p. administration. We have developed a reverse-phase high performance liquid chromatography assay for PEN, and subsequently investigated murine pharmacokinetics and metabolism. Following rapid i.v. injection of PEN (300 mg/m2) to mice, plasma elimination was best described by a 2-compartment open model with an elimination phase half-life, total body clearance, and steady-state distribution volume of 69 min, 114 ml/min/m2, and 4800 ml/m2, respectively. While PEN displayed good p.o. absorption, bioavailability of PEN after p.o. administration was approximately 2% of that observed following i.v. administration. Metabolism contributed substantially to drug clearance, and total metabolites were slowly eliminated from plasma. After i.v. and p.o. administration of radiolabeled PEN, <0.2% of the parent drug was excreted in the 48-h urine, and 25-30% of the total radioactivity was recovered in urine. NADPH-dependent oxidative and reductive metabolism was observed when penclomedine was incubated with mouse microsomal preparations. Microsomal reductive metabolism of PEN led to formation of a metabolite tentatively identified as a molecule formed by dimerization of the radical species produced by cleavage of chlorine from the trichloromethyl moiety of penclomedine.

AB - Penclomedine, a highly substituted pyridine derivative, has been selected by the National Cancer Institute for evaluation as a potential anticancer agent based on antitumor activity observed in murine tumor models following i.v., p.o., and i.p. administration. We have developed a reverse-phase high performance liquid chromatography assay for PEN, and subsequently investigated murine pharmacokinetics and metabolism. Following rapid i.v. injection of PEN (300 mg/m2) to mice, plasma elimination was best described by a 2-compartment open model with an elimination phase half-life, total body clearance, and steady-state distribution volume of 69 min, 114 ml/min/m2, and 4800 ml/m2, respectively. While PEN displayed good p.o. absorption, bioavailability of PEN after p.o. administration was approximately 2% of that observed following i.v. administration. Metabolism contributed substantially to drug clearance, and total metabolites were slowly eliminated from plasma. After i.v. and p.o. administration of radiolabeled PEN, <0.2% of the parent drug was excreted in the 48-h urine, and 25-30% of the total radioactivity was recovered in urine. NADPH-dependent oxidative and reductive metabolism was observed when penclomedine was incubated with mouse microsomal preparations. Microsomal reductive metabolism of PEN led to formation of a metabolite tentatively identified as a molecule formed by dimerization of the radical species produced by cleavage of chlorine from the trichloromethyl moiety of penclomedine.

UR - http://www.scopus.com/inward/record.url?scp=0026643627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026643627&partnerID=8YFLogxK

M3 - Article

C2 - 1581896

AN - SCOPUS:0026643627

VL - 52

SP - 2830

EP - 2834

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 10

ER -